CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07Submission of Matters to a Vote of Security Holders.

On June 8, 2017, Corvus Pharmaceuticals,Inc. (the Company) held
its 2017 Annual Meeting of Stockholders (the Annual Meeting) at
863 Mitten Road, Suite 102, Burlingame, California 94010. Only
stockholders of record at the close of business on April 17,
2017, the record date for the Annual Meeting, were entitled to
vote at the Annual Meeting. As of the record date, there were
20,934,514 shares of the Companys common stock outstanding and
entitled to vote at the Annual Meeting. At the Annual Meeting,
19,075,230 shares of the Companys common stock were voted in
person or by proxy for the four proposals set forth below, each
of which is described in the Companys Definitive Proxy Statement
on Schedule 14A filed with the U.S. Securities and Exchange
Commission on April 24, 2017.

The tabulation of the stockholder votes on each proposal brought
before the Annual Meeting is as follows:

Proposal No.1 Election of Directors

The Companys stockholders elected the ClassI director nominees
below to the Companys Board of Directors to hold office until the
2020 Annual Meeting of Stockholders or until their respective
successors are elected and qualified or appointed, or the earlier
of their death, resignation or removal.

Proposal No.2 Ratification of Selection of
Independent Registered Accounting Firm

The Companys stockholders ratified the selection of
PricewaterhouseCoopers LLC as the independent registered public
accounting firm of the Company for its fiscal year ending
December31, 2017.

Proposal No.3 Ratification of the Companys Amended
and Restated Certificate of Incorporation

The Companys stockholders ratified the Companys Amended and
Restated Certificate of Incorporation.

Proposal No.4 Ratification of the Companys Amended
and Restated Bylaws

The Companys stockholders ratified the Companys Amended and
Restated Bylaws.

About CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.